Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-08-23Clinical Trial Update: Incidence of Hyperpigmentation in Black Patients With Multiple Myeloma Treated With Immunomodulatory Drugs
This clinical trial update reports the incidence of hyperpigmentation in Black patients with multiple myeloma treated with immunomodulatory …
-
CLINICAL_TRIALS trial_result · 2024-08-22Clinical Trial Update: Metformin, Nelfinavir, and Bortezomib in Treating Patients With Relapsed and/or Refractory Multiple Myeloma [Phase 1]
This Phase 1 study evaluated the safety and preliminary efficacy of combining metformin, nelfinavir, and bortezomib in patients with relapse…
-
CLINICAL_TRIALS trial_result · 2024-08-16Clinical Trial Update: The TOTOM Trial: Tai Chi to Optimize Transplant Outcomes for Multiple Myeloma [NA]
Clinical trial update for the TOTOM Trial evaluating Tai Chi to optimize transplant outcomes in multiple myeloma. The study status is comple…
-
CLINICAL_TRIALS trial_result · 2024-08-13Clinical Trial Update: Finistere Myeloma Observatory (OMYFIN)
The Finistere Myeloma Observatory (OMYFIN) trial for multiple myeloma has completed enrollment. The sponsor is University Hospital, Brest.
-
CLINICAL_TRIALS trial_result · 2024-08-02Clinical Trial Update: Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma [Phase 1, Phase 2]
Clinical trial update for AT7519M alone and in combination with bortezomib in previously treated multiple myeloma (Phase 1/Phase 2; complete…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-08-01Clinical Trial Update: Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial [Phase 3]
A Phase 3 trial (OPTIMUM) tested adding ixazomib or placebo to lenalidomide in patients with residual multiple myeloma. The study has comple…
-
CLINICAL_TRIALS trial_result · 2024-08-01Clinical Trial Update: Evaluation of IGM-2644 in Adults With Relapsed and/or Refractory Multiple Myeloma [Phase 1]
The Phase 1 study evaluating IGM-2644 in adults with relapsed and/or refractory multiple myeloma was terminated.
-
CLINICAL_TRIALS trial_result · 2024-08-01Clinical Trial Update: Ixazomib, Lenalidomide, and Combination for Maintenance in NDMM Patients [Phase 4]
Phase 4 maintenance trial in newly diagnosed multiple myeloma evaluating ixazomib, lenalidomide, and the combination.
-
CLINICAL_TRIALS trial_result · 2024-08-01Clinical Trial Update: The clonoSEQ® Watch Registry
Clinical trial update for the clonoSEQ Watch Registry sponsored by Adaptive Biotechnologies; the study status is terminated.
-
CLINICAL_TRIALS trial_result · 2024-07-30Clinical Trial Update: A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment [Phase 2]
Phase 2 trial update evaluating elranatamab in relapsed or refractory multiple myeloma; results are posted.
-
CLINICAL_TRIALS trial_result · 2024-07-26Clinical Trial Update: Phase I: Melphalan, Bendamustine and Carfilzomib for Autologous Transplant in Multiple Myeloma [Phase 1]
Phase I study evaluating a melphalan, bendamustine, and carfilzomib regimen for autologous stem cell transplantation in multiple myeloma; th…
-
CLINICAL_TRIALS trial_result · 2024-07-26Clinical Trial Update: A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma [Phase 1]
A Phase 1 study evaluating CC-98633, a BCMA-targeted CAR T-cell therapy, in relapsed and/or refractory multiple myeloma has completed.
-
CLINICAL_TRIALS trial_result · 2024-07-25Clinical Trial Update: Dose-escalation Study of Oral Administration of S 55746 in Patients With Chronic Lymphocytic Leukaemia and B-Cell Non-Hodgkin Lymphoma [Phase 1]
Phase I dose-escalation study of oral S-55746 in patients with chronic lymphocytic leukemia and B-cell non-Hodgkin lymphoma completed.
-
CLINICAL_TRIALS trial_result · 2024-07-25Clinical Trial Update: Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies [Phase 1]
Tinostamustine, a first-in-class alkylating HDAC inhibitor fusion molecule, completed its Phase 1 study in relapsed/refractory hematologic m…
-
CLINICAL_TRIALS trial_result · 2024-07-24Clinical Trial Update: A Study of Real-World Use of Ixazomib Citrate in People With Multiple Myeloma (MM)
A real-world study evaluating ixazomib citrate in people with multiple myeloma has completed. The sponsor is Takeda.
-
CLINICAL_TRIALS trial_result · 2024-07-22Clinical Trial Update: Lenalidomide Melphalan and Prednisone Versus High Dose Melphalan in Newly Diagnosed Multiple Myeloma Patients [Phase 3]
This entry reports the completion of a Phase 3 randomized trial comparing lenalidomide, melphalan, and prednisone versus high-dose melphalan…
-
CLINICAL_TRIALS trial_result · 2024-07-22Clinical Trial Update: STUDY TO DETERMINE THE EFFICACY AND SAFETY OF STANDARD SCHEDULE VERSUS A NEW ALGORITHM OF DOSE REDUCTIONS IN ELDERLY AND UNFIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING LENALIDOMIDE PLUS STEROIDS [Phase 3]
Phase 3 clinical trial comparing a standard dosing schedule to a new dose-reduction algorithm in elderly and unfit newly diagnosed multiple …
-
CLINICAL_TRIALS trial_result · 2024-07-16Clinical Trial Update: Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma [Phase 2]
A Phase 2 clinical trial update reports results of a quadruplet regimen combining daratumumab, carfilzomib, lenalidomide, and dexamethasone …
-
CLINICAL_TRIALS trial_result · 2024-07-12Clinical Trial Update: Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma [Phase 2]
Results from a Phase 2 trial of the panobinostat, bortezomib, and dexamethasone combination in relapsed or relapsed-and-refractory multiple …
-
CLINICAL_TRIALS trial_result · 2024-07-11Clinical Trial Update: Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma [Phase 1]
DCR-MYC, an investigational therapy, was evaluated in a Phase I multicenter dose-escalation study in patients with solid tumors, multiple my…
-
CLINICAL_TRIALS trial_result · 2024-07-09Clinical Trial Update: Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma [Phase 1]
Phase 1 clinical trial update on ACY-241 given alone or in combination with pomalidomide and dexamethasone in multiple myeloma; the study st…
-
CLINICAL_TRIALS trial_result · 2024-07-09Clinical Trial Update: GIC-102, Intravenous Allogeneic NK Cells, in Subjects With Advanced Solid Cancers and R/R Hematologic Malignancies [Phase 1, Phase 2]
GIC-102, an intravenously administered allogeneic NK cell therapy, is being evaluated in Phase 1/Phase 2 trials for advanced solid tumors an…
-
CLINICAL_TRIALS trial_result · 2024-07-08Clinical Trial Update: A Study to Investigate the Relationship Between Duration of Treatment and Response in Patients With Multiple Myeloma (MM) or Systemic AL Amyloidosis Treated in Real-life Practice
This completed clinical trial studied how the duration of treatment relates to patient response in real-world cases of multiple myeloma or l…
-
CLINICAL_TRIALS trial_result · 2024-07-03Clinical Trial Update: Precision Medicine for Patients With Identified Actionable Mutations [Phase 2]
A Phase 2 precision medicine trial for patients with identified actionable mutations in solid tumors, lymphoma, and multiple myeloma was ter…
-
CLINICAL_TRIALS trial_result · 2024-07-03Clinical Trial Update: Oral ONC201 in Relapsed/Refractory Multiple Myeloma [Phase 1, Phase 2]
A Phase 1/2 trial evaluating oral ONC201 in relapsed/refractory multiple myeloma was terminated, with results posted in 2024.